Year-end report May – April 2011/12

  · Order bookings increased to SEK 10,815 M (9,061), equivalent to 10* percent
excluding Nucletron.
  · Net sales increased to SEK 9,048 M (7,904), equivalent to 7* percent
excluding Nucletron. Including Nucletron net sales grew by 18* percent whereof
Nucletron contributed with 11 percentage points.
  · Operating result increased by 22 percent to SEK 1,837 M (1,502) excluding
non-recurring items of SEK 12 M (−) (see page 4).
  · Net income increased by 19 percent to SEK 1,228 M (1,031). Earnings per
share amounted to SEK 13.04 (11.04) before dilution and SEK 12.91 (10.91) after
dilution.
  · Cash flow from operating activities decreased by 24 percent to SEK 635 M
(840). Cash flow after investments was SEK -2 663 M (491), including acquisition
effects of SEK -3 166 M (-259).
  · The board proposes a dividend of SEK 5.00 (4.00) per share, corresponding to
around SEK 473 M and 39 percent of net profit.
  · On September 15, 2011, Elekta completed the acquisition of Nucletron, world
leader in brachytherapy treatment planning and delivery.
  · On September 30, 2011, Elekta divested its pathology business, PowerPath®.
The net gain amounted to SEK 180 M based on current exchange rate.
  · During the fourth quarter, a convertible bond issue was conducted, with
preferential rights for the company’s shareholders. The issue was fully
subscribed and raised approximately SEK 1,894 M for the company, before
transaction costs.
  · For fiscal year 2012/13, net sales is expected to grow by more than 15
percent in local currency, including Nucletron. Operating profit in SEK is
expected to grow by more than 17 percent. Currency is estimated to have a
positive effect of about SEK 50 M including hedging effects on earnings for
fiscal year 2012/13.

* Compared to last fiscal year at unchanged exchange rates.

Table included in attached PDF file

President and CEO comments
I am delighted with and proud of Elekta’s performance in the fourth quarter and
for the full-year 2011/12. Our focus on continuously advancing cancer care
solutions in cooperation with our customers, combined with strategic investments
in emerging markets, generated favorable results. Fourth-quarter order bookings
rose 11* percent and to 10* percent for the full-year. The full-year trend was
particularly strong in North and South America with an increase of 11* percent,
and in Asia, where order bookings rose 14* percent. Our assessment is that we
are growing faster than the market as a whole and thus strengthening our market
position.

During the fourth quarter, we received clearance to CE mark our new multi-leaf
collimator Agility, enabling patients in Europe to now benefit from treatments
using the new solution. Agility is a revolutionary system aimed at improving
cancer treatment and entails significant advantages for both patients and
hospitals. In the US, we have applied for 510(k) clearance of Agility.

Similar to the preceding quarter, deliveries in the fourth quarter were
favorable and net sales rose 11* percent. For the full-year, including
Nucletron, growth in local currencies totaled 18 percent, of which the
acquisition of Nucletron accounted for about 11 percentage points.

The operating result rose 22 percent for the full-year. Nucletron contributed
with approximately 13 percentage points to the increase. The operating margin
improved by one percentage point to 20 percent, primarily as a result of the
leveraging that higher volumes have on the fixed cost base.

The initial phase of the strategic review of Elekta’s MEG operations is
completed. We remain strongly committed to the clinical MEG community and when
improvements have been fully implemented, we assume strengthened financial
performance.

Elekta foresees significant potential for further growth, both through expansion
in emerging markets and through improved market positions in established
markets. Looking to the year ahead, we believe that market demand will generally
remain favorable. The trend in emerging markets is expected to be strong and the
positive trend in North America is expected to continue. The recent financial
debt crisis in Europe is assessed as only having had a limited impact on market
conditions so far. The demand scenario in Europe is mixed, with a continued
robust trend in northern regions and in emerging markets, while the trend in
southern regions is expected to be weaker. The recent announcement by one of the
major competitors to exit the market for linear accelerators is expected to
further improve Elekta’s growth opportunities.

Elekta is stronger than ever and I am looking forward to the coming fiscal year
with confidence. We will continue our efforts to improve our cancer care
solutions with a focus on patients and continue to pursue our growth strategy.
For the fiscal year 2012/13, net sales is expected to grow by more than 15
percent in local currency, including Nucletron. The operating result in SEK is
expected to grow by more than 17 percent. Currency is estimated to have a
positive effect of about SEK 50 M. We look forward to even more patients gaining
access to advanced cancer care for cure and a better quality of life.

Tomas Puusepp
President and CEO

*Excluding Nucletron and based on unchanged exchange rates

Elekta’s year-end report conference call
Elekta will host a telephone conference 10.00-11.00 CET on June 5, with
President and CEO Tomas Puusepp and CFO Håkan Bergström.
To take part in the conference call, please dial in about 5-10 minutes in
advance and use the access code 917247. Swedish dial-in number: +46 (0)8 5052
0110, UK dial-in number: +44 (0)20 7162 0077, US dial-in number: + 1 334 323
6201.
The telephone conference will also be broadcasted over the Internet (listen
only). Please use the link http://webeventservices.reg.meeting
-stream.com/64156_elekta

For further information, please contact:
Håkan Bergström, CFO, Elekta AB (publ)
+46 8 587 25 547, hakan.bergstrom@elekta.com

Stina Thorman, Vice President Corporate Communications, Elekta AB (publ)
08 587 254 37, stina.thorman@elekta.com

Johan Andersson Melbi, Investor Relations Manager, Elekta AB (publ)
+46 8 587 25 415, johan.anderssonmelbi@elekta.com

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07.30 CET on June 5, 2012.